EGFR-mutated NSCLC first-line intervention usually includes a variety of EGFR-TKI, namely, 1st-generation EGFR-TKI (gefitinib, erlotinib and icotinib), 2nd-generation EGFR-TKI (dacomitinib and afatinib), and 3rd-generation EGFR-TKI (osimertinib, furmonertinib, almonertinib) [6–9]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.